GRAYBUG VISION INC (GRAY) Stock Price & Overview
NASDAQ:GRAY • US38942Q1031
Current stock price
The current stock price of GRAY is 5.5 USD. Today GRAY is down by -10.8%. In the past month the price decreased by -37.39%. In the past year, price decreased by -69.78%.
GRAY Key Statistics
- Market Cap
- 617.26K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.66
- Dividend Yield
- N/A
GRAY Stock Performance
GRAY Stock Chart
GRAY Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GRAY. When comparing the yearly performance of all stocks, GRAY is a bad performer in the overall market: 93.68% of all stocks are doing better.
GRAY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GRAY. GRAY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GRAY Earnings
GRAY Forecast & Estimates
6 analysts have analysed GRAY and the average price target is 42.84 USD. This implies a price increase of 678.91% is expected in the next year compared to the current price of 5.5.
GRAY Groups
Sector & Classification
GRAY Financial Highlights
Over the last trailing twelve months GRAY reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS increased by 1.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
GRAY Ownership
GRAY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.01 | 874.551B | ||
| JNJ | JOHNSON & JOHNSON | 20.49 | 580.403B | ||
| MRK | MERCK & CO. INC. | 22.8 | 298.788B | ||
| PFE | PFIZER INC | 9.05 | 158.307B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.19 | 120.824B | ||
| ZTS | ZOETIS INC | 16.62 | 49.921B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.08 | 27.297B | ||
| VTRS | VIATRIS INC | 5.28 | 15.44B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.41 | 11.345B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.682B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.421B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.091B | ||
| CORT | CORCEPT THERAPEUTICS INC | 49.39 | 4.345B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRAY
Company Profile
Graybug Vision Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Redwood City, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The firm's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The firm is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.
Company Info
IPO: 2020-09-25
GRAYBUG VISION INC
274 Redwood Shores Parkway, P.O. Box 144
Redwood City CALIFORNIA 94065 US
CEO: Frederic Guerard
Employees: 8
Phone: 16504872800.0
GRAYBUG VISION INC / GRAY FAQ
Can you describe the business of GRAYBUG VISION INC?
Graybug Vision Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Redwood City, California and currently employs 8 full-time employees. The company went IPO on 2020-09-25. Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases. The firm's products include GB-102 and GB-401. GB-102 is a lead product designed to provide pan-vascular endothelial growth factor (VEGF) inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments. GB-102 is a once-every-six month intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). The firm is also evaluating and developing GB-102 for the treatment of diabetic retinopathy (DR). GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor designed to provide a controlled release of the active drug to maintain reduced intraocular pressure (IOP) for six months or longer after a single injection for the treatment of primary open-angle glaucoma.
Can you provide the latest stock price for GRAYBUG VISION INC?
The current stock price of GRAY is 5.5 USD. The price decreased by -10.8% in the last trading session.
What is the dividend status of GRAYBUG VISION INC?
GRAY does not pay a dividend.
What is the ChartMill rating of GRAYBUG VISION INC stock?
GRAY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of GRAYBUG VISION INC (GRAY) based on its PE ratio?
GRAYBUG VISION INC (GRAY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).
Should I buy GRAY stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GRAY.